Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALVO Alvotech	$8.79 -3.0%	$9.54	$7.35 ▼ $13.70	$2.73B	0.11	330,311 shs	285,194 shs
DNA Ginkgo Bioworks	$12.18 -7.3%	$10.05	$5.00 ▼ $16.85	$769.11M	1.5	1.59 million shs	1.36 million shs
RXRX Recursion Pharmaceuticals	$5.68 -4.5%	$5.28	$3.79 ▼ $12.36	$2.42B	0.93	31.26 million shs	17.93 million shs
TWST Twist Bioscience	$33.68 +0.3%	$34.67	$27.12 ▼ $55.33	$2.01B	2.37	891,336 shs	1.38 million shs

10 Stocks Set to Soar in Summer 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALVO Alvotech	-2.98%	-8.53%	-1.57%	+6.93%	-24.87%
DNA Ginkgo Bioworks	-7.04%	-12.72%	-3.87%	+73.01%	-19.87%
RXRX Recursion Pharmaceuticals	-4.54%	-12.48%	+9.02%	-0.35%	-30.73%
TWST Twist Bioscience	+0.33%	-6.42%	-10.62%	-14.17%	-39.65%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALVO Alvotech	3.3884 of 5 stars	3.5	4.0	0.0	3.4	0.0	1.9
DNA Ginkgo Bioworks	1.1775 of 5 stars	1.0	3.0	0.0	1.9	2.5	1.3
RXRX Recursion Pharmaceuticals	1.5365 of 5 stars	2.2	2.0	0.0	3.3	1.7	0.6
TWST Twist Bioscience	3.5578 of 5 stars	3.4	0.0	4.4	3.3	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALVO Alvotech	3.00	Buy	$14.00	59.27% Upside
DNA Ginkgo Bioworks	2.00	Hold	$8.50	-30.21% Downside
RXRX Recursion Pharmaceuticals	2.33	Hold	$7.00	23.24% Upside
TWST Twist Bioscience	2.70	Moderate Buy	$50.40	49.64% Upside

Current Analyst Ratings Breakdown

Latest DNA, TWST, ALVO, and RXRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/18/2025	ALVO Alvotech	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$16.00 ➝ $14.00
7/8/2025	RXRX Recursion Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
7/3/2025	RXRX Recursion Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Equal Weight	$5.00
6/16/2025	RXRX Recursion Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$8.00 ➝ $5.00
5/6/2025	RXRX Recursion Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$11.00 ➝ $8.00
5/6/2025	TWST Twist Bioscience	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$55.00 ➝ $48.00
5/6/2025	TWST Twist Bioscience	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00 ➝ $50.00
5/6/2025	TWST Twist Bioscience	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$54.00 ➝ $44.00
5/6/2025	TWST Twist Bioscience	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$40.00 ➝ $33.00

(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALVO Alvotech	$491.98M	5.39	N/A	N/A	($1.37) per share	-6.42
DNA Ginkgo Bioworks	$227.04M	3.14	N/A	N/A	$13.17 per share	0.92
RXRX Recursion Pharmaceuticals	$58.84M	39.24	N/A	N/A	$2.61 per share	2.18
TWST Twist Bioscience	$312.97M	6.45	N/A	N/A	$8.07 per share	4.17

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALVO Alvotech	-$231.86M	$0.37	23.76	43.95	N/A	16.42%	-36.37%	12.70%	8/21/2025 (Estimated)
DNA Ginkgo Bioworks	-$547.03M	-$9.16	N/A	N/A	N/A	-198.84%	-52.35%	-27.14%	8/7/2025 (Estimated)
RXRX Recursion Pharmaceuticals	-$463.66M	-$1.77	N/A	N/A	N/A	-961.32%	-74.70%	-54.02%	8/5/2025 (Estimated)
TWST Twist Bioscience	-$208.73M	-$3.25	N/A	N/A	N/A	-54.98%	-33.48%	-25.34%	8/4/2025 (Confirmed)

Latest DNA, TWST, ALVO, and RXRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/21/2025	Q2 2025	ALVO Alvotech	-$0.06	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	DNA Ginkgo Bioworks	-$1.44	N/A	N/A	N/A	$41.60 million	N/A
8/5/2025	Q2 2025	RXRX Recursion Pharmaceuticals	-$0.34	N/A	N/A	N/A	$15.38 million	N/A
8/4/2025	Q3 2025	TWST Twist Bioscience	-$0.54	N/A	N/A	N/A	$95.52 million	N/A
5/7/2025	Q1 2025	ALVO Alvotech	-$0.17	$0.35	+$0.52	$0.35	N/A	N/A
5/6/2025	Q1 2025	DNA Ginkgo Bioworks	-$1.23	-$1.58	-$0.35	-$1.68	$38.70 million	$48.32 million
5/5/2025	Q1 2025	RXRX Recursion Pharmaceuticals	-$0.44	-$0.50	-$0.06	-$0.50	$18.12 million	$14.75 million
5/5/2025	Q2 2025	TWST Twist Bioscience	-$0.56	-$0.66	-$0.10	-$0.66	$92.00 million	$92.79 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALVO Alvotech	N/A	N/A	N/A	N/A	N/A
DNA Ginkgo Bioworks	N/A	N/A	N/A	N/A	N/A
RXRX Recursion Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TWST Twist Bioscience	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALVO Alvotech	N/A	1.73	1.19
DNA Ginkgo Bioworks	N/A	4.88	4.88
RXRX Recursion Pharmaceuticals	0.02	4.11	4.11
TWST Twist Bioscience	0.03	4.51	4.24

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALVO Alvotech	N/A
DNA Ginkgo Bioworks	78.63%
RXRX Recursion Pharmaceuticals	89.06%
TWST Twist Bioscience	N/A

Insider Ownership

Company	Insider Ownership
ALVO Alvotech	0.46%
DNA Ginkgo Bioworks	9.72%
RXRX Recursion Pharmaceuticals	8.43%
TWST Twist Bioscience	3.01%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALVO Alvotech	1,032	301.48 million	300.10 million	Not Optionable
DNA Ginkgo Bioworks	640	58.53 million	52.84 million	Optionable
RXRX Recursion Pharmaceuticals	400	406.49 million	372.23 million	Optionable
TWST Twist Bioscience	990	59.92 million	58.11 million	Optionable

DNA, TWST, ALVO, and RXRX Headlines

Recent News About These Companies

Preview: Twist Bioscience's Earnings

2 hours ago | benzinga.com

Twist Bioscience Corporation (NASDAQ:TWST) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

August 1 at 2:39 AM | americanbankingnews.com

Twist Bioscience Expands In Vivo Antibody Discovery Services with Launch of Humanized Transgenic Mouse Model

July 31 at 6:52 PM | finance.yahoo.com

Is There An Opportunity With Twist Bioscience Corporation's (NASDAQ:TWST) 27% Undervaluation?

July 31 at 4:52 AM | finance.yahoo.com

Is Twist Bioscience Corp. (TWST) Nearing Profitability?

July 28, 2025 | msn.com

Twist Bioscience (TWST) to Release Earnings on Monday

July 28, 2025 | marketbeat.com

Envestnet Asset Management Inc. Has $2.76 Million Position in Twist Bioscience Corporation (NASDAQ:TWST)

July 28, 2025 | marketbeat.com

ARK Investment Management LLC Acquires 645,730 Shares of Twist Bioscience Corporation (NASDAQ:TWST)

July 27, 2025 | marketbeat.com

Nikko Asset Management Americas Inc. Sells 197,166 Shares of Twist Bioscience Corporation (NASDAQ:TWST)

July 27, 2025 | marketbeat.com

Baillie Gifford & Co. Has $28.74 Million Holdings in Twist Bioscience Corporation (NASDAQ:TWST)

July 27, 2025 | marketbeat.com

Twist Bioscience Corporation (NASDAQ:TWST) Given Average Recommendation of "Moderate Buy" by Brokerages

July 27, 2025 | marketbeat.com

TWST vs. NTRA: Which Genomics Play Is a Better Buy?

July 25, 2025 | 247wallst.com

Cwm LLC Has $639,000 Stake in Twist Bioscience Corporation (NASDAQ:TWST)

July 24, 2025 | marketbeat.com

Twist Bioscience Corporation (NASDAQ:TWST) Position Trimmed by Jennison Associates LLC

July 21, 2025 | marketbeat.com

Bank of New York Mellon Corp Has $21.25 Million Stake in Twist Bioscience Corporation (NASDAQ:TWST)

July 18, 2025 | marketbeat.com

Twist Bioscience Corporation (NASDAQ:TWST) Shares Bought by New York State Common Retirement Fund

July 17, 2025 | marketbeat.com

Principal Financial Group Inc. Trims Holdings in Twist Bioscience Corporation (NASDAQ:TWST)

July 17, 2025 | marketbeat.com

Twist Bioscience: Still Not There Yet

July 15, 2025 | seekingalpha.com

Twist Bioscience to Report Fiscal 2025 Third Quarter Financial Results on Monday, August 4, 2025

July 14, 2025 | businesswire.com

Twist Bioscience Corporation (NASDAQ:TWST) CFO Adam Laponis Sells 2,449 Shares

July 11, 2025 | marketbeat.com

Emily M. Leproust Sells 476 Shares of Twist Bioscience Corporation (NASDAQ:TWST) Stock

July 8, 2025 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

DNA, TWST, ALVO, and RXRX Company Descriptions

Alvotech NASDAQ:ALVO

$8.79 -0.27 (-2.98%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$8.79 0.00 (0.00%)

As of 08/1/2025 06:31 PM Eastern

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.

Ginkgo Bioworks NYSE:DNA

$12.18 -0.96 (-7.31%)

Closing price 08/1/2025 03:59 PM Eastern

Extended Trading

$12.17 -0.01 (-0.08%)

As of 08/1/2025 07:52 PM Eastern

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Recursion Pharmaceuticals NASDAQ:RXRX

$5.68 -0.27 (-4.54%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$5.62 -0.06 (-1.06%)

As of 08/1/2025 08:00 PM Eastern

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Twist Bioscience NASDAQ:TWST

$33.68 +0.11 (+0.33%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$33.98 +0.30 (+0.89%)

As of 08/1/2025 06:52 PM Eastern

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time